Approximate 30-day mortalities and treatment considerations
+1 → 3%, outpatient treatment
+2 →7%, inpatient, possible outpatient
+3 → 14% inpatient, possible ICU
+4-5 → 30% ICU
+1 → 3%, outpatient treatment
+2 →7%, inpatient, possible outpatient
+3 → 14% inpatient, possible ICU
+4-5 → 30% ICU
CURB-65
Limp 
MHH-TMC
Rho
PALS 
SCVMC:EXC
Hirudins
Tdap